Loading...
Loading...
Of the 4 tracked institutions holding PMCB, 2 have a 3-year clone track record — 2 of them beat the S&P. Average holder's clone alpha: +8.4pt. It's a gauge of who owns the name, not just how many.
Alpha = the manager's 3-year clone return minus the S&P 500. A skilled roster is a stronger tell than a crowded one — though even skilled managers' edge doesn't reliably survive the 13F disclosure lag. Why →
Among the 4 tracked institutional investors we monitor, PMCB (PHARMACYTE BIOTECH INC) is held with a combined value of $331.08K across 490,967 shares. The largest holder is CITADEL ADVISORS LLC with a position worth $239.24K. 1 fund increased its holdings. 1 fund reduced its position.
Total Institutional Value
$331.08K
Total Shares Held
490,967
Institutional Holders
4
Ranked by estimated dollars moved (share change × implied price). 13F data lags up to 45 days.
| # | Fund | Value↓ | Portfolio % | Change |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | $239.24K | 0.00% | +56.5% |
| 2 | VANGUARD GROUP INC | $54.24K | 0.00% | - |
| 3 | RENAISSANCE TECHNOLOGIES LLC | $37.59K | 0.00% | -39.9% |
| 4 | BlackRock, Inc. | $1 | 0.00% | - |
As of the latest SEC 13F filings, CITADEL ADVISORS LLC is the largest institutional holder of PMCB with a position worth $239.24K, representing 0.00% of their portfolio. In total, 4 institutional investors hold PMCB with a combined value of $331.08K.
Institutional investors hold $331.08K worth of PMCB stock across 4 positions. The largest institutional holder is CITADEL ADVISORS LLC with $239.24K in holdings.
A 13F filing is a quarterly report required by the SEC from institutional investment managers with over $100 million in assets. It discloses their holdings in U.S. equities. For PMCB, these filings reveal which major funds are accumulating or reducing positions, providing insights into institutional sentiment.
Get notified when hedge funds change their PMCB positions.
Last Close
$0.60
2026-07-24
YTD
-18.7%
0% of 52-week range
